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Abstract 
Background: Hepatitis C virus (HCV) genotypes have been shown to be differently distributed between distinct 
geographical areas. Libya is a large country has the longest coast in the Mediterranean basin. Information regard‑
ing hepatitis C genotypes and subtypes circulating in Libya are not well known. The objectives of this study were to 
determine the frequency of various HCV genotypes cross Libya and the demographic and attributable risk factors 
associated with HCV transmission among Libyan population.
Methods: A cross‑sectional study was carried out on patients with recently confirmed HCV infection. A total of 3,227 
serum samples enrolled at 19 collection center cross Libya. 1,756 belonged to Tripoli region, 452 to West region 355 to 
North region, 181 South regions and 483 East region. The samples were tested by type specific genotyping assay and 
correlated with demographic and potential risk factors within the studied populations.
Results: A total of 20 discrete genotypes and subtypes were identified among the Libyan population ranging from 
11.5 to 0.3 % cross the country. Genotype 1 was the most frequent among all regions (19.7–40.5 %), reaching the 
highest value in Tripoli region, followed by genotype 4 which was more prevalent in the South (49.3 %) and West 
(40.0 %) regions. Genotype 3, was higher in Tripoli (21.3 %) and East (15.9 %) regions while genotype 2, common in 
North (23.6 %) and South (22.5 %) regions. However, we found evidence that there is a changing relative prevalence 
of HCV genotypes in relation to age, gender and the mode of transmission which is reflected in the predominance of 
certain genotypes among Libyan population.
Conclusions: Different HCV genotypes were isolated form Libyan population including newly emerged ones. The 
prevalence of the genotypes varied by geographic region and influenced by demographic and risk factors. Knowing 
the frequency and distribution of the genotypes would provide key information on understanding the spread of HCV 
in Libya and this could be greatly reflected on national plans and future strategies for infection prevention.
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Background
Hepatitis C virus (HCV) is a leading cause of chronic 
viral hepatitis, liver cirrhosis and hepatocellular carci-
noma. Such implications have great, clinical, epidemio-
logical and economic burdens worldwide particularly 
among developing countries [1, 2]. Relative risk factors as 
well as intervention and preventions programs are greatly 
influenced by regional variation of the HCV genotypes 
[3]. Genotyping plays an important role in the patho-
genicity and hepatocarcinogenic potential of hepatitis C 
infection. Indeed pathological consequences and thera-
peutic responses has been greatly influenced by the HCV 
genotypes [4].
Different studies have shown that HCV genotype 1 has 
been associated with lower rates of response to peginter-
feron-based regimens compared with genotypes 2 and 
3. Furthermore, infections with genotype 1a responds 
less than genotype 1b to treatment with peginterferon/
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ribavirin and to triple regimens that include telaprevir 
or boceprevir [5, 6]. Differences in pathogenicity and 
hepatocarcinogenic potential of the various genotypes 
of HCV were also reported. Raimondi et  al. found that 
there was an increased risk of HCC in patients infected 
with genotype 1b, with or without the presence of cir-
rhosis [7]. Other studies also found both subtypes within 
genotype 1 to confer heightened risk of histopathological 
damage, concomitant progression to HCC, and to a lesser 
extent, persistence of infection [8, 9]. Many of these stud-
ies are from geographical regions where such genotypes 
predominate, hence then, further studies from different 
regions are needed.
The relative prevalence of HCV genotyping varies geo-
graphically and demographically worldwide. HCV geno-
types 1a and 1b, are the most frequent genotypes in the 
North American and Europe [10, 11], and genotypes 
5 and 6 seem to be confined to South Africa and Hong 
Kong [12, 13], respectively. HCV genotypes 7, 8, and 9 
have been identified only in Vietnamese patients [14, 15] 
and genotypes 10 and 11 were identified in patients from 
Indonesia [16]. HCV genotypes and subtypes within the 
country also vary according to ethnicity and age. How-
ever, world integration and recent massive population 
displacement has lead to introduction of HCV genotype 
among a certain areas that not commonly known. HCV 
genotype distribution has been used for the identification 
of populations’ origin of HCV infection, examination of 
historical trends in characteristics of HCV infection and 
making inferences regarding routes of HCV transmission 
[17].
Hepatitis C virus infection is a major public health 
concern among African countries, they have the high-
est prevalence rates of HCV in the world, ranging from 
1 to 26 % [2, 18]. Over 28 million people are chronically 
infected with HCV in this continent, and it is difficult 
to speculate about current and future trends [19]. HCV 
genotyping rarely studied in Africa, however, few stud-
ies were carried on a restricted populations in North 
Africa have shown diversity of HCV genotyping among 
these countries [20]. Therefore, population based stud-
ies are needed in order to plan for future prevention 
and intervention programs. Libya is the second larg-
est country in Africa, with the longest coast facing 
the Southern European Union [21]. Bordering six dif-
ferent countries, where HCV has been considered to 
be endemic [22, 23]. In recent years the country has 
attracted worldwide attention because many Africans 
transit through it to enter Southern Europe illegally, 
with the possibility of transmitting infection in transit, 
or at the destination. Hence then a wide variation in 
the frequencies of HCV genotypes would be expected 
among Libyan territory.
In Libya HCV has been well studied, recently a com-
prehensive study including 1  % of the total population 
was carried. HCV prevalence ranged from 0.9 to 1.2 %. It 
was most prevalent among intravenous drug users (7.4 %) 
and less prevalent but still substantial in those undergo-
ing blood transfusion (2.7 %), surgical operation (2.3 %) 
or hospital admission (1.9 %) [24]. However, few studies 
had lend themselves studying HCV genotype frequencies 
in small cohorts or restricted populations, but informa-
tion concerning the distribution of viral genotypes and 
demographic and risk factors that influence HCV infec-
tion are limited [20]. The objectives of this study were 
aimed to determine the distribution of various HCV gen-
otypes and subtypes present in different geo-graphical 
regions of Libya and the association with various risk fac-




Serum samples were collected from different patients 
with chronic HCV from all Libyan provinces based on 
the population proportion. Libya is a large country with a 
total geographic area; 1,775,500 km2 (square kilometers). 
The estimated Libyan population based on the consensus 
of 2006 was found to be 6,154,623 million. More than half 
of population were located in Tripoli region and less than 
a million in the Eastern region, the others are scattered 
over the vast areas of the country. A total of 3,227 dif-
ferent sera samples were collected from each of the five 
regions as following:
  • Tripoli Region (TR) represented by five districts 
[number of isolates (n) =  1,756] including: Tajoura, 
Old City, Zwara, Alzawia, and Tarhona.
  • West Region (WR) represented by three districts 
(n) = 452 including: Navosa Mountains, Garian and 
Ghadams.
  • North Region (NR) represented by four districts 
(n) = 355 including: Sert, Musrata, Alkoms and Bani-
waled.
  • South Region (SR) represented by four districts 
(n)  =  181 including: Aljofra, Ashati, Murzak and 
Sebha.
  • East Region (ER) represented by three districts 
(n) = 483 including: Benghazi, Albtnan and Alkufra.
Laboratory tests and HCV genotyping
All the serum samples were received along with spe-
cifically designed data sheets at Department of Medi-
cal Microbiology, Faculty of Medicine, Tripoli from 19 
tertiary collection of the 5 regions involved. A written 
informed consent was taken from each patient and the 
Page 3 of 9Daw et al. BMC Res Notes  (2015) 8:367 
data sheet contained demographic information including 
age, gender, year of diagnosis and risk factors for HCV 
such as history of blood transfusion, intravenous drug 
abuse (IVDA), history of surgical intervention, family his-
tory of HCV positive and history of promiscuity and den-
tal procedure. Those patients who denied any risk factors 
were assigned to be as an; unknown group. Each serum 
specimen was re-tested positive for HCV antibody (anti-
HCV) using 3rd generation commercial Enzyme Linked 
Immunosorbent Assays as previously described by Daw 
and El-Bouzedi [24]. HCV genotyping was carried out 
using type-specific HCV genotyping method [20]. All the 
different genotypes of HCV were tested and primers for 
genotypes 1a, 1b, 1c, 3a, 3c and 4 and 2a, 2c, 3b, 5a, and 
6a primers were incorporated. Hence then HCV geno-
type for each sample was determined by identifying the 
HCV genotype-specific PCR band [20].
Statistical analysis
Data were coded and entered into a data base, which was 
then cleaned and verified. Data were analysed by using 
the Chi square test with Yates’ correction or Student’s 
t-test for univariate analysis. The results for all variables 
were given in the form of rates (%). A multivariate anal-
ysis was conducted using logistic regression in order to 
verify which variables statistically had an influence on 
HCV infection such as gender (male vs. female), IV drug 
abuser (yes or no), blood transfusion (yes o r no) surgi-
cal Intervention and blood transfusion (yes or no), dental 
care (yes or no); promiscuity (yes or no). The data were 
analyzed using SPSS version 11.5 to identify the distribu-
tion of different genotypes and it s association with gen-
der, age, year of diagnosis and risk factors [20].
Ethical approval
The study was approved by the Libyan National Ethi-
cal Committee (Approval No. LY NS; HCV-G-399773). 
It was conducted in accordance with the Helsinki Dec-
laration [25] and under the supervision of the Faculty 
of Medicine, Tripoli, Libya. All participants signed an 
informed consent form witnessed by the local health 
office before collection of data and blood samples. The 
questionnaire used to collect demographic and epide-
miological data was anonymous and linked to the blood 
sample tube only by a code.
Results
A total of 3,227 anti-HCV positive sera were received 
from all the five regions of the country. Out of these 
1,501 (46 %) samples were found positive by HCV quali-
tative PCR with viral load >500  IU/ml were tested by 
type-specific genotyping assay. Out of 1,501 patients, 
976 (65 %) were males and 525 (35 %) were females with 
an average age of 37.8 ± 13.4 years. Total of 817 (54.4 %) 
belongs to Tripoli region, 161 (10.7 %) to North region, 
210 (13.9  %) West region, 71 (4.7  %) South region, 242 
(15.1  %) East region. The distribution of HCV geno-
types was shown in Table 1; a total of 20 different HCV 
genotypes and subtypes were found among the Libyan 
population. The distribution of such types was found to 
be as follows: 371 (11.5 %) were genotype 4; 219 (6.7 %) 
genotype 1; 205 (6.35 %) genotype 1b; 199 (6.17 %) gen-
otype 3a; 135 (4.18  %) genotype 1a; 118 (3.66  %) geno-
type 2; (82 %) genotype 2a/c; 68 (2.11) genotype 4c/d; 40 
(1.24 %) genotype 3;19 (0.59 %) genotype 4h; 15 (0.46 %) 
genotype 2b; 10 (0.31 %) genotype 2a; 7 (0.22 %) genotype 
4e; and 4 (0.12 %) genotype 4a. Few stains were isolated 
at a low count (0.3 %) these include genotype 4b, 4f, 4h, 
4d, 4a/c and HCV genotype 5 though genotype 6 was not 
reported.
HCV genotype 1, 2, 3 and 4 were isolated from all over 
Libya, Fig.  1 shows the distribution of such genotypes 
according to the patients residential regions. Genotype 
1 is the most common genotype isolated from Tripoli 
(40.5 %) and East regions (38.4 %), followed by the West 
(35.2 %) and North (31.1 %) regions and less reported in 
the South region (19.7 %); Genotype 4, South (49.3 %) and 
West region (40.0  %), followed by both East and North 
Table 1 Distribution of  HCV genotypes and  subtypes 
among Libyan populations




1 219 (6.79) 160 (7.26) 59 (5.77)
1a 135 (4.18) 103 (4.67) 32 (3.13)
1b 205 (6.35) 110 (4.99) 95 (9.29)
1a/b 3 (0.09) 2 (0.09) 1 (0.10)
2 118 (3.66) 72 (3.27) 46 (4.50)
2a 10 (0.31) 4 (0.18) 6 (0.59)
2b 15 (0.46) 8 (0.36) 7 (0.68)
2a/c 83 (2.57) 49 (2.22) 34 (3.32)
3 40 (1.24) 33 (1.50) 7 (0.68)
3a 199 (6.17) 170 (7.71) 29 (2.83)
4 371 (11.50) 216 (9.80) 155 (15.15)
4b 4 (0.12) 1 (0.14) 0 (0.10)
4e 1 (0.03) 6 (0.05) 1 (0.00)
4F 7 (0.22) 1 (0.27) 0 (0.10)
4h 19 (0.59) 8 (0.36) 11 (1.08)
4a/c 1 (0.03) 0 (0.00) 1 (0.10)
4c/d 68 (2.11) 29 (1.32) 39 (3.81)
4d 1 (0.03) 1 (0.05) 0 (0.00)
5 1 (0.03) 1 (0.05) 0 (0.00)
Unknown 1,726 (53) 1,227 (55.67) 499 (48.78)
Total 3,227 (100.00) 2,204 (100.00) 1,023 (100.00)
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(35.5 %) and less among Tripoli region (25.9); Genotype 
3, Tripoli (21.3  %) and East (15.9  %) and varied from 
7.1 to 11.6  % among other regions; Genotype 2, North 
(23.6  %) and South (22.5  %) and from 12.2 to 14.5  % 
among other regions. HCV genotypes were found to be 
variables among the Libyan region involved (P  <  0.26) 
though no variation within the provinces of each region.
Table 2 illustrates the association between HCV geno-
types and demographic variables (i.e. age distribution) 
among Libyan population. HCV genotype 1 was more 
frequent genotype among all age groups ranged from 25.3 
to 88 %, followed by genotype 4 ranged from 8 to 37.6 % 
while genotype 2 and 3 are less frequent ranged from 
0 to 45.5  % and 4 to 25.5  % respectively. Furthermore, 
HCV genotype 1 was the highest among those below 
(<20  years); 88  % within (0–9  years) and 78  % of (10–
19  years). HCV genotype 2 was three times (OR =  0.2; 
95 %CI 0.1–0.5, P < 0.001) higher among those aged over 
50 comparable to a younger age population. Genotype 
3 was twice higher among those aged 20–40 year of age 
Fig. 1 Geographical distribution of HCV genotypes according to the Libyan regions (color‑coded). Data indicate percentage of patients infected by 
genotype in each region.
Table 2 The distribution of  HCV-genotypes among  differ-
ent age group
Age group Genotype 1 Genotype 2 Genotype 3 Genotype 4 Total
0–9 22 (88.0) 0 (0.0) 1 (4.0) 2 (8.0) 25
10–19 46 (78.0) 2 (3.4) 2 (3.4) 9 (15.3) 59
20–29 113 (39.6) 29 (10.2) 53 (18.6) 90 (31.6) 285
30–39 199 (35.3) 44 (7.8) 144 (25.5) 177 (31.4) 564
40–49 109 (38.0) 41 (14.3) 29 (10.1) 108 (37.6) 287
50–59 40 (25.8) 55 (35.5) 6 (3.9) 54 (34.8) 155
60–69 25 (25.3) 45 (45.5) 3 (3.0) 26 (26.3) 99
70–79 8 (29.6) 10 (37.0) 1 (3.7) 8 (29.6) 27
Total 562 (37.4) 226 (15.1) 239 (15.9) 474 (31.6) 1,501
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than the other age groups. Figure  2 shows the distribu-
tion of HCV genotypes among different age groups.
Figure 3 shows the influence of gender on the distri-
bution of HCV genotypes among Libyans. Hepatitis 
C virus genotypes, 1, 4 and 3 are the common among 
both sexes. HCV-genotype 1 is highest among males 
(38.4 %), while genotype 4 is the highest among females 
(39.7 %). HCV subtypes were also influenced by gender 
variations. Subtype 1a, 1b, 1a/b, subtype 2a/c, 3a, 4a, 
4b, 4f were found to be more common among males. 
Though subtype 2a, subtype 4h, 4a/c and subtype 4c/d 
were common among females. Hepatitis C genotypes 
vary from 1  year to another as shown in Fig.  4. Geno-
types 1 and 4 we the commonly isolated one during the 
study period while genotypes 2 and 3 are slightly vari-
able (P > 0.0025).
Table 3 shows the correlation between HCV-genotypes 
and the risk factors involved in the populations studied. 
HCV genotype 2 and genotype 3 were more frequent 
among intravenous drug abuse (IVDUs) comparable 
to non-users (non-IVUDs)-(IVUDs vs non-IVUDs) as 
it was found to be (49.2 vs 36.3 %) and (32.6 vs 14.3 %) 
respectively. Genotype 4 was more frequent among cae-
sarean section comparable to those not operated (50 vs 
14.3 %; P < 0.0001). Non of other risk factor were found 
to be significantly associated with any of HCV genotypes 
(P  <  0.26). Multiple risk factors were identified among 
9.5 % (6.1–2.3 % among the different age groups) of the 
subjects, where 7.4  % of them had two risk factors and 
2.1  % had three risk factors. There are no risk factors 
found in 40.9 % of the patients under the study ranging 
from 37.1 to 51 % in the different age groups.
Fig. 2 The distribution of HCV genotypes among different age groups of Libyan populations.
Fig. 3 The influence of gender on the distribution of HCV genotypes among Libyans.
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Discussion
Hepatitis C virus genotyping has been found to play an 
important role in understanding the epidemiology, guid-
ing the clinical therapy, vaccine development and assess-
ing the risk–benefit of HCV infection [26–28]. In recent 
decades there has been a global epidemic of some of 
these genotypes and subtypes assembled with certain risk 
factors and modern medical practice [3, 4]. Regional dif-
ferences appear to exist in the distribution of HCV geno-
types. Such variability are rarely studied in Africa where 
habitual and ethnic variation exist and HCV is considered 
to be endemic [29]. Hence then studying distribution 
Fig. 4 Distribution of hepatitis C genotype during the period of 2000–2006.
Table 3 Prevalence of HCV Genotype according to risk factors among Libyan population, * P = 0.26
Risks exposure Genotype 1 Genotype 2 Genotype 3 Genotype 4 Total P value*
Sexual
 No 551 (37.3) 225 (15.2) 234 (15.8) 467 (31.6) 1,477 0.424
 Yes 11 (45.8) 1 (4.2) 5 (20.8) 7 (29.2) 24
Cesarean section
 No 549 (37.7) 222 (15.2) 235 (16.1) 451 (31.0) 1,457 0.26
 Yes 13 (29.5) 4 (9.1) 4 (9.1) 23 (52.3) 44
Intravenous drug use
 No 497 (36.3) 226 (16.5) 196 (14.3) 450 (32.9) 1,369 0.000
 Yes 65 (49.2) 0 (0) 43 (32.6) 24 (18.2) 132
Blood transfusion
 No 420 (37.1) 167 (14.8) 196 (17.3) 348 (30.8) 1,131 0.071
 Yes 142 (38.4) 59 (15.9) 43 (11.6) 126 (34.1) 370
Surgery
 No 457 (38.1) 171 (14.3) 198 (16.5) 372 (31.1) 1,198 0.165
 Yes 105 (34.7) 55 (18.2) 41 (13.5) 102 (33.7) 303
Dental procedure
 No 490 (37.5) 193 (14.8) 204 (15.6) 418 (32.0) 1,305 0.641
 Yes 72 (36.7) 33 (16.8) 35 (17.9) 56 (28.6) 196
Intrafamilial
 No 549 (37.4) 222 (15.1) 232 (15.8) 463 (31.6) 1,466 0.876
 Yes 13 (37.1) 4 (11.4) 7 (20.0) 11 (31.4) 35
Haemodialysis
 No 551 (37.5) 225 (15.3) 234 (15.9) 460 (31.3) 1,470 0.185
 Yes 11 (35.5) 1 (3.2) 5 (16.1) 14 (45.2) 31
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of various genotypes in this continent is essential for its 
prognostic implications in chronic hepatitis C infection.
In this cross-sectional epidemiologic study, with strati-
fied sampling we investigated the distribution of vari-
ous HCV genotypes in Libya, and the potential links 
with demographic and transmission risk factors. Our 
results indicate that HCV genotype 1 (37.4 %) is the most 
prevalent genotype cross Libya followed by genotypes 4 
(31.6 %) and to less extent genotypes 3 and 2 and infre-
quent cases of genotype 5. This however, is in agree-
ment in previous studies carried by our group though 
with a lower population size [20]. A substantial regional 
differences appear to exist in the distribution of HCV 
genotypes cross Libya. Genotype 1 and 3 were higher 
in Tripoli, and East regions though less among the oth-
ers particularly south regions. Genotype 4 was higher in 
South and West regions while genotype 2 more prevalent 
in North and South regions. Such data correspondence 
well with other studies from different countries that have 
shown the genotypic regional diversity of HCV [30]. Gen-
otypes 1 and 3 of Tripoli region were found to be similar 
to those in south Italy and Greece [31, 32]. Though geno-
type 4 of the South and East regions were also common 
in Egypt and other neighboring African countries [33]. 
Genotypes 2 and 3 were found to be more frequent in 
the South and North regions may suggest presence of 
foreigners living illegally in Libya, due to uncontrolled 
borders. Libya, however, is considered to be biggest seat 
for illegal transition immigration to EU particularly dur-
ing the recent uprising and uncontrolled armed conflicts 
[19, 34]. Thus knowledge on the distribution of various 
genotypes in such country is essential for its prognostic 
implications in chronic hepatitis C infection. Hence then 
further study are needed to document the changes of 
HCV genotypes variability over periods of time.
The distribution of HCV genotypes in this study was 
influenced by gender. Genotypes 1 (M:F; 38.4:35.7  %), 
3 (20.8:6.9) and 4 (17.6:14) were higher among males. 
Although few distinct subtypes within genotype 4 were 
more predominant among females particularly 4h 
(0.36:1.08) and 4c/d (1.32:3.81) while genotype 2 was 
more frequent among females (13.6:17.7). Our results 
are in concordance with a recently published data from 
other countries including Italy and Germany [35, 36]. 
However, most of those participated in the study were 
males (65:35). This may reflect the conservative nature of 
Libyan society and highlights the need to improve sam-
pling techniques particularly among women sectors in 
the upcoming surveys.
Considering the age group distribution, the present 
study indicates that HCV genotype distribution var-
ies with age. HCV genotype 1 is highly predominant 
among younger patients (<20  years). It reached 88 and 
78 % among those aged (0–9 years) and (10–19) respec-
tively. Genotype 2 was tripled among those aged above 
50, although genotype 3 was significantly higher among 
those aged 20–40  years. Genotype 4 was evenly dis-
tributed in all age groups particularly over 20 years old. 
Different studies have analyzed the correlation of HCV 
genotypes in relation to the patients age. Similar results 
were also reported in other North African countries. 
In Algeria, genotype 1 is associated with the age group 
younger than 60 years though other genotypes types are 
higher among older age groups [37]. The frequency of 
genotypes and their variation according to age groups 
were clearly evident among the Libyan populations which 
was not reported before and thus appears to confirm the 
‘stratification’ of genotypes associated with risk factors 
reported in the literature [2, 19, 20].
Different studies have suggested HCV genotypes may 
be associated with different transmission routes and high 
risk behaviors. Transmission by IVDUs is most common 
in Libya, and has become more frequent and associated 
with genotype 1 (49.2 %) and genotype 3 (32.6 %) infec-
tions. Studies from neighboring countries also found 
an association between genotype 1 and IVDUs but not 
genotype 3. However, it has also been reported that HCV 
genotype 3 is particularly prevalent in intravenous drug 
abusers in Europe and the United States due to wide 
spread use of heroin [38, 39]. The identification of geno-
type 3 among Libyan population reflected its worldwide 
occurrence among PWID. Further studies are needed to 
highlight the spread of this genotype particularly among 
the young people. Genotype 4 was significantly associ-
ated with Caesarian section (52.3  %) and intra-family 
transmission (31.4  %). Both genotype 1 and 4 were the 
predominant genotypes among medical practice includ-
ing blood transfusion (1:4; 38.4:34.1), surgical practice 
procedures (34.7:33.1), dental practice (33:18.2) and hae-
modialysis (45.8:45.2). This is in agreement with other 
studies from different countries where majority of the 
cases with genotype 1 has a history of hospitalization for 
major/minor surgery, dental procedures, received blood 
and/or blood products and shaving by barbers [40–42].
In this study, over 15 HCV subtypes were identified 
including newly emerged ones such as 1a/b, 4b, 4e, 4f, 4h, 
4a/c, 4d, 4c/d and HCV genotype 5. The distribution of 
these subtypes among the Libyan regions and their asso-
ciation with demographic and behavioral correlates were 
explored. Subtypes 1a, 1b and 3a are more predominant 
in Tripoli region (i.e. Old City and Bosleam) and East 
region (i.e. Benghazi) particularly among young males 
(<30  years) with history of IVDUs. This is in an agree-
ment with other studies from America and Southern 
Europe countries who also found a higher percentage of 
individuals infected with HCV subtypes 1a, 1b, and 3a, 
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are among IVDUs [43, 44]. HCV subtypes 4a, 4e, 4h and 
4c/d more frequent in South and East regions of Libya 
and associated with hospital and modern medical prac-
tices. Genotype 4 is considered to be endemic in North 
Africa and Meddle-East and rarely reported in other 
regions and thus more likely to be associated with com-
mon public-health and family practices. However, further 
studies are needed to highlight the association of these 
subtypes with education levels and living standards con-
ditions among such countries [3, 19].
Our study mirrors clearly the HCV genotypic diversity 
among Libyan populations. Such, genotyping profile vari-
ability may reflect differences in the timing of acquisition 
of HCV infection that may in turn influence the timing of 
the peak burden of HCV complications including cirrhosis 
and hepato-cellular carcinoma. As a consequence of these 
trends, regional differences in HCV genotype prevalence 
and epidemiology may warrant consideration of prevention 
and treatment strategies that are tailored to local needs [45].
The main limitations of this study that the correlation 
between HCV genotypes and the severity of the diseases 
among the studied population is lacking. Previous reports 
have shown that evidence of advanced liver disease and 
increased risk of hepatocellular carcinoma were more 
common in patients with HCV genotype 1 and 1b than 
other genotypes [46, 47]. Hence then future studies es are 
recommended to highlight such correlation particularly 
among naïve patients [48]. Additionally this study did not 
identify patients with possible HCV/HIV co-infection and 
HCV genotypes involved. Different studies have shown 
that the distribution of HCV genotypes in the HIV-
infected population reflects the route of transmission and 
progression to both AIDS and death [49]. Genotype 1b 
associated with post-transfusion HIV infections and gen-
otypes 1a and 3a are more common in intravenous drug 
users infected with HIV [50]. Furthermore, genotype 1 
and 3 were associated with severe histopathological and 
steatohepatitis findings in HIV/HCV-co-infected patients 
and leads to significantly faster HIV progression [51].
Conclusion
In conclusion regional difference in HCV genotypes were 
clearly evident among Libyan population with emerg-
ing of new genotypes, though genotypes 1 and 4 are 
more dominant. The frequency of these genotype are 
significantly associated with demographic and risk fac-
tors involved. Furthermore, the spread of intravenous 
drug use could have led to a new wave of HCV infec-
tion among young people. Therefore, a future evaluation 
of new ‘emerging’ subtypes over a period of time will be 
necessary, particularly nowadays as the country passing 
by difficult situations resulting in a massive population 
displacement and immigration engulfment [52].
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